Fate Therapeutics (FATE) News Today $0.96 -0.04 (-4.00%) As of 04:00 PM Eastern Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock FATE Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 Time Period Integral Health Asset Management LLC Lowers Holdings in Fate Therapeutics, Inc. (NASDAQ:FATE)Integral Health Asset Management LLC cut its position in Fate Therapeutics, Inc. (NASDAQ:FATE - Free Report) by 38.5% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 600,000 shares of the biopharmacMay 14 at 6:18 AM | marketbeat.comFate Therapeutics Reports First Quarter 2025 Financial Results and Business UpdatesMay 13 at 4:01 PM | globenewswire.comFate Therapeutics: Suffering The Fate Of A Depressed Cell Therapy SectorMay 9, 2025 | seekingalpha.comBaker BROS. Advisors LP Grows Position in Fate Therapeutics, Inc. (NASDAQ:FATE)Baker BROS. Advisors LP lifted its position in shares of Fate Therapeutics, Inc. (NASDAQ:FATE - Free Report) by 8.7% during the 4th quarter, according to its most recent disclosure with the SEC. The firm owned 3,258,402 shares of the biopharmaceutical company's stock after buying an additional 260,May 6, 2025 | marketbeat.comFate Therapeutics, Inc. (NASDAQ:FATE) Given Average Rating of "Hold" by BrokeragesShares of Fate Therapeutics, Inc. (NASDAQ:FATE - Get Free Report) have been assigned a consensus recommendation of "Hold" from the nine ratings firms that are covering the company, MarketBeat Ratings reports. Seven investment analysts have rated the stock with a hold recommendation and two have givMay 4, 2025 | marketbeat.comFate Therapeutics (FATE) Expected to Announce Quarterly Earnings on ThursdayFate Therapeutics (NASDAQ:FATE) will be releasing its Q1 2025 earnings before the market opens on Thursday, May 8. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2025-5-8-fate-therapeutics-inc-stock/)May 3, 2025 | marketbeat.comMarshall Wace LLP Makes New Investment in Fate Therapeutics, Inc. (NASDAQ:FATE)Marshall Wace LLP bought a new position in shares of Fate Therapeutics, Inc. (NASDAQ:FATE - Free Report) during the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor bought 512,641 shares of the biopharmaceutical company's stock, valued at approximaMay 3, 2025 | marketbeat.comFate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)May 2, 2025 | globenewswire.comFate Therapeutics Announces Five Presentations on Off-the-Shelf CAR T-cell Product Platform at ASGCT Annual MeetingApril 29, 2025 | globenewswire.comRecent uptick might appease Fate Therapeutics, Inc. (NASDAQ:FATE) institutional owners after losing 66% over the past yearApril 27, 2025 | finance.yahoo.com249,800 Shares in Fate Therapeutics, Inc. (NASDAQ:FATE) Acquired by XTX Topco LtdXTX Topco Ltd bought a new stake in Fate Therapeutics, Inc. (NASDAQ:FATE - Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 249,800 shares of the biopharmaceutical company's stock, valued at apprApril 24, 2025 | marketbeat.comWalleye Capital LLC Has $1.79 Million Position in Fate Therapeutics, Inc. (NASDAQ:FATE)Walleye Capital LLC grew its holdings in Fate Therapeutics, Inc. (NASDAQ:FATE - Free Report) by 1,502.0% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,083,092 shares of the biopharmaceutical company's stock aftApril 22, 2025 | marketbeat.comCerity Partners LLC Grows Holdings in Fate Therapeutics, Inc. (NASDAQ:FATE)Cerity Partners LLC boosted its holdings in shares of Fate Therapeutics, Inc. (NASDAQ:FATE - Free Report) by 4,953.6% during the 4th quarter, according to its most recent 13F filing with the SEC. The fund owned 823,134 shares of the biopharmaceutical company's stock after purchasing an additional 8April 20, 2025 | marketbeat.comFate Therapeutics receives RMAT designation from FDA for FT819April 14, 2025 | markets.businessinsider.comFate Therapeutics Stock Draws Investor Attention After FDA Grants Special Designation To Its CAR T-Cell Therapy: Retail Stays OptimisticApril 14, 2025 | msn.comFate Therapeutics gets RMAT status from FDA for Lupus treatmentApril 14, 2025 | msn.comFate Therapeutics Receives Regenerative Medicine Advanced Therapy (RMAT) Designation from FDA for FT819 to Treat Moderate to Severe Systemic Lupus Erythematosus (SLE)April 14, 2025 | globenewswire.comFate Therapeutics, Inc. (NASDAQ:FATE) Receives Average Recommendation of "Hold" from AnalystsShares of Fate Therapeutics, Inc. (NASDAQ:FATE - Get Free Report) have earned an average rating of "Hold" from the nine ratings firms that are covering the firm, MarketBeat reports. Seven analysts have rated the stock with a hold rating and two have issued a buy rating on the company. The averageApril 8, 2025 | marketbeat.comFate Therapeutics (NASDAQ:FATE) Stock Crosses Below 200 Day Moving Average - Here's What HappenedFate Therapeutics (NASDAQ:FATE) Share Price Passes Below 200-Day Moving Average - Here's What HappenedApril 5, 2025 | marketbeat.comFate Therapeutics (FATE) Down 34.6% Since Last Earnings Report: Can It Rebound?April 4, 2025 | msn.comFate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)April 2, 2025 | globenewswire.comFY2025 EPS Forecast for Fate Therapeutics Boosted by AnalystFate Therapeutics, Inc. (NASDAQ:FATE - Free Report) - Analysts at Cantor Fitzgerald boosted their FY2025 EPS estimates for Fate Therapeutics in a note issued to investors on Tuesday, March 18th. Cantor Fitzgerald analyst L. Watsek now anticipates that the biopharmaceutical company will post earniMarch 21, 2025 | marketbeat.comFate Therapeutics’ SWOT analysis: promising pipeline drives stock outlookMarch 14, 2025 | investing.comFate Therapeutics (NASDAQ:FATE) Rating Lowered to "Sell" at StockNews.comStockNews.com downgraded shares of Fate Therapeutics from a "hold" rating to a "sell" rating in a report on Tuesday.March 11, 2025 | marketbeat.comBank of America Securities Keeps Their Hold Rating on Fate Therapeutics (FATE)March 10, 2025 | markets.businessinsider.comFate Therapeutics price target lowered to $2.50 from $3 at BofAMarch 10, 2025 | markets.businessinsider.comQ1 EPS Estimates for Fate Therapeutics Boosted by WedbushFate Therapeutics, Inc. (NASDAQ:FATE - Free Report) - Stock analysts at Wedbush raised their Q1 2025 EPS estimates for Fate Therapeutics in a research report issued to clients and investors on Wednesday, March 5th. Wedbush analyst D. Nierengarten now expects that the biopharmaceutical company wilMarch 10, 2025 | marketbeat.comFate Therapeutics, Inc. (NASDAQ:FATE) Just Reported, And Analysts Assigned A US$6.00 Price TargetMarch 8, 2025 | finance.yahoo.comFate Therapeutics, Inc Q4 Loss Misses EstimatesMarch 8, 2025 | nasdaq.comFate Therapeutics (NASDAQ:FATE) Price Target Lowered to $3.00 at Stifel NicolausStifel Nicolaus lowered their price objective on Fate Therapeutics from $5.00 to $3.00 and set a "hold" rating for the company in a research report on Thursday.March 7, 2025 | marketbeat.comFate Therapeutics (NASDAQ:FATE) Given New $4.00 Price Target at Wells Fargo & CompanyWells Fargo & Company lowered their target price on shares of Fate Therapeutics from $5.00 to $4.00 and set an "equal weight" rating on the stock in a report on Thursday.March 7, 2025 | marketbeat.comFate Therapeutics (NASDAQ:FATE) Earns "Neutral" Rating from WedbushWedbush reissued a "neutral" rating and issued a $5.00 price target on shares of Fate Therapeutics in a report on Thursday.March 7, 2025 | marketbeat.comNeedham & Company LLC Reiterates "Hold" Rating for Fate Therapeutics (NASDAQ:FATE)Needham & Company LLC reissued a "hold" rating on shares of Fate Therapeutics in a research note on Thursday.March 7, 2025 | marketbeat.comWedbush Remains a Hold on Fate Therapeutics (FATE)March 7, 2025 | markets.businessinsider.comFate Therapeutics (NASDAQ:FATE) Releases Earnings Results, Beats Expectations By $0.13 EPSFate Therapeutics (NASDAQ:FATE - Get Free Report) posted its earnings results on Wednesday. The biopharmaceutical company reported ($0.31) EPS for the quarter, topping the consensus estimate of ($0.44) by $0.13. Fate Therapeutics had a negative net margin of 1,325.43% and a negative return on equity of 45.88%.March 6, 2025 | marketbeat.comFate Therapeutics (NASDAQ:FATE) Issues Quarterly Earnings ResultsFate Therapeutics (NASDAQ:FATE - Get Free Report) posted its quarterly earnings data on Wednesday. The biopharmaceutical company reported ($0.31) EPS for the quarter, beating analysts' consensus estimates of ($0.44) by $0.13. Fate Therapeutics had a negative net margin of 1,325.43% and a negative return on equity of 45.88%.March 6, 2025 | marketbeat.comStifel Nicolaus Sticks to Their Hold Rating for Fate Therapeutics (FATE)March 6, 2025 | markets.businessinsider.comFate Therapeutics price target lowered to $3 from $5 at StifelMarch 6, 2025 | markets.businessinsider.comFate Therapeutics reports Q4 EPS (44c), consensus (42c)March 6, 2025 | markets.businessinsider.comFate Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business UpdatesMarch 5, 2025 | globenewswire.comStockNews.com Upgrades Fate Therapeutics (NASDAQ:FATE) to HoldStockNews.com raised Fate Therapeutics from a "sell" rating to a "hold" rating in a research note on Monday.March 4, 2025 | marketbeat.comFate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4)March 4, 2025 | globenewswire.comFate Therapeutics (FATE) Projected to Post Earnings on MondayFate Therapeutics (NASDAQ:FATE) will be releasing earnings before the market opens on Monday, February 24, Financial Modeling Prep reports.February 22, 2025 | marketbeat.comFate Therapeutics (FATE) Projected to Post Quarterly Earnings on MondayFate Therapeutics (NASDAQ:FATE) will be releasing earnings before the market opens on Monday, February 24, Financial Modeling Prep reports.February 17, 2025 | marketbeat.comFY2024 Earnings Forecast for FATE Issued By Leerink PartnrsFate Therapeutics, Inc. (NASDAQ:FATE - Free Report) - Leerink Partnrs issued their FY2024 EPS estimates for Fate Therapeutics in a report released on Thursday, February 13th. Leerink Partnrs analyst D. Graybosch anticipates that the biopharmaceutical company will post earnings per share of ($1.62February 17, 2025 | marketbeat.comFate Therapeutics, Inc. (NASDAQ:FATE) Receives Consensus Rating of "Hold" from AnalystsFate Therapeutics, Inc. (NASDAQ:FATE - Get Free Report) has earned an average recommendation of "Hold" from the ten research firms that are presently covering the firm, MarketBeat reports. Seven research analysts have rated the stock with a hold rating and three have assigned a buy rating to theFebruary 16, 2025 | marketbeat.comResearch Analysts Offer Predictions for FATE Q1 EarningsFate Therapeutics, Inc. (NASDAQ:FATE - Free Report) - Investment analysts at Leerink Partnrs issued their Q1 2025 earnings per share estimates for Fate Therapeutics in a research note issued on Thursday, February 13th. Leerink Partnrs analyst D. Graybosch anticipates that the biopharmaceutical coFebruary 15, 2025 | marketbeat.comFate Therapeutics to Present at Upcoming Investor ConferencesFebruary 14, 2025 | globenewswire.comAnalysts Conflicted on These Healthcare Names: Sanofi (OtherSNYNF) and Fate Therapeutics (FATE)February 14, 2025 | markets.businessinsider.comSpringworks Therapeutics (SWTX) Gets a Buy from BarclaysFebruary 11, 2025 | markets.businessinsider.com Get Fate Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for FATE and its competitors with MarketBeat's FREE daily newsletter. Email Address FATE Media Mentions By Week FATE Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. FATE News Sentiment▼0.390.80▲Average Medical News Sentiment FATE News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. FATE Articles This Week▼83▲FATE Articles Average Week Get Fate Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for FATE and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Mind Medicine (MindMed) News Ginkgo Bioworks News Arvinas News Taysha Gene Therapies News Cullinan Therapeutics News Eton Pharmaceuticals News Altimmune News Sana Biotechnology News MeiraGTx News Maze Therapeutics News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:FATE) was last updated on 5/14/2025 by MarketBeat.com Staff From Our PartnersSilver Demand Is Soaring-Supply Can't Keep UpSilver demand hit 1.16 billion ounces in 2024-while supply fell short again for the fourth year in a row. I...i2i Marketing Group, LLC | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredElon just did WHAT!?As you may recall, Biden and the Fed were working on a central bank digital currency, or CBDC. Had they got...Brownstone Research | Sponsored“America is running out of power” - The Washington PostAccording to The Washington Post, AI is causing America to “run out of power”... It’s true — utility compan...True Market Insiders | SponsoredTrump Made a Deal. Your Retirement Could Still Be in Danger.America is still barreling toward a financial cliff. This isn't political. It's mathematical. And no trade ...Lear Capital | SponsoredBITCOIN Liquidity pools are the backbone of crypto—and right now, they’re exploding with activity. By providing liqui...Awesomely, LLC | SponsoredShocking AI play that’s beats Nvidia by a country mileYou’ve seen the headlines about Nvidia. Now Tim Sykes is sounding the alarm — because what CEO Jensen Huang is...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Fate Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Fate Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
